SciClone's strategic goal is to become the principal worldwide provider of immune system enhancers as monotherapies and as critical components of combination drug therapies for infectious diseases and cancer. Other drugs in SciClone's pipeline are intended to protect and expand this franchise and to address the protein-based disorder that causes cystic fibrosis.